<DOC>
	<DOCNO>NCT02719743</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity different formulation GSK Biologicals ' influenza candidate vaccine GSK1557484A , child 6-35 month age .</brief_summary>
	<brief_title>A Dose Ranging Safety Immunogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' GSK1557484A Vaccine Children 6 Less Than 36 Months Age</brief_title>
	<detailed_description>Safety immunogenicity different formulation administer 2-dose schedule child 6-35 month age evaluate . In addition , quality 2-dose priming assess anamnestic response elicit antigen challenge ( unadjuvanted H5N1 ) administer 12 month later . The persistence immune response approximately 12 month ( Day 385 ) dose 2 also evaluate . Subjects group enrol CMI sub-cohort comprise approximately 100 subject . Within participate country ( y ) , subject enrol selected/qualified site .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject 's parent ( ) / Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . Male female child 6 month le 36 month old time first vaccination . Children 36 month old Day 0 , day first vaccine dose protocol , enrol . Written inform consent obtain parent ( ) /legally acceptable representative ( ) [ LAR ( ) ] subject prior performance study specific procedure . Healthy subject establish medical history standard physical examination enter study . Born fullterm confirm interview parent/LAR available medical record . Child care . Medical history physicianconfirmed infection H5N1 virus . Previous vaccination time H5N1 vaccine . Concurrently participate another clinical study , use investigational nonregistered vaccine , pharmaceutical product , device within 30 day precede first dose study vaccine , plan use study period . Presence parent ( ) / LAR ( ) evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render parent ( ) /LAR ( ) unable/unlikely provide accurate safety report . Acute disease and/or fever time enrolment . Administration immunoglobulins , blood product , longacting immunemodifying drug period start 3 month first dose study vaccine , plan administration study period . History neurological disorder seizure , GuillainBarré Syndrome . Diagnosed excessive daytime sleepiness narcolepsy ; history narcolepsy subject 's parent sibling . Administration inactive vaccine within 14 day live attenuated vaccine within 30 day first vaccination . Planned administration vaccine foreseen study protocol Day 0 Day 42 plan administration inactive vaccine within 14 day live attenuated vaccine within 30 day 30 day booster vaccination . Note : routine vaccination may provide Day 42 study assessment perform . History reaction hypersensitivity likely exacerbate component vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Any medical condition judgment investigator would make intramuscular injection unsafe . Chronic administration immunosuppressant immunemodifying drug period start six month prior first vaccine . For corticosteroid , mean dose prednisone equivalent &gt; 2 mg/kg/day body weight ≥ 20 mg/day ( person weigh ≥ 10 kg ) . Inhaled topical steroid allow . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . Major congenital defect . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>child</keyword>
	<keyword>H5N1</keyword>
	<keyword>observer-blind</keyword>
	<keyword>Influenza</keyword>
	<keyword>dose-ranging</keyword>
</DOC>